No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 361 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab June 11, 2021 Young Mom Battles Breast Cancer After Being Misdiagnosed with a Blocked... July 30, 2019 “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 Load more HOT NEWS FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma EMA Grants a Marketing Authorisation for Two Biosimilar Medicines, Bevacizumab After 5 Years of Follow-Up, the Median PFS Has Yet To...
